InflaRx N.V.

InflaRx N.V. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. InflaRx N.V. is a mediocre stock to choose.
Log in to see more information.
InflaRx NV is a biopharmaceutical company, which engages in the discovery and development of inhibit...
IFRX Fundamental Data by TradingView

News

InflaRx (NASDAQ:IFRX) Shares Up 1.3%
InflaRx (NASDAQ:IFRX) Shares Up 1.3%

Ticker Report InflaRx (NASDAQ:IFRX - Get Free Report) shares shot up 1.3% during mid-day trading on Tuesday . The company traded as high as $1.65 and last traded at $1.61. 57,793 shares changed hands during...\n more…

InflaRx presents new preclinical findings for INF904
InflaRx presents new preclinical findings for INF904

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Globe Newswire JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...\n more…

InflaRx Announces Participation in September Investor Events
InflaRx Announces Participation in September Investor Events

Globe Newswire JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...\n more…

InflaRx Buy Rating Backed by Promising Drug Prospects and Financial Stability
InflaRx Buy Rating Backed by Promising Drug Prospects and Financial Stability

TipRanks Financial Blog Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on InflaRx (IFRX - Research Report), retaining the price target of $5.00. Josep...\n more…

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research InflaRx N.V. (IFRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.15 per share a year ago. These figures are...\n more…